RE:J and J Tar 200 claiming a high CR % for NMIBCPretty simple their results are superior to ours. TLT has blundered their way through this which has allowed everyone to catch up and surpass them. Beyond the obvious such as insanely low enrollment rates and dosing the drug incorrectly, they also either have been unable or unwilling to partner with anyone else which is mind blowing since their patent runs out in the not so distant future so at some point why would someone want to partner for a viral or lung/brain indication if by judging by its history the patent will nearly be expired by the time the trials are done.